These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32095474)

  • 1. Pharmacokinetics of atorvastatin and sustained-release metformin fixed-dose combination tablets: two randomized, open-label, 2-way crossover studies in healthy male subjects under fed conditions.
    Choi YK; Park SE; Kim EY; Park HJ; Kim EJ; Song GS; Ghim JL
    Transl Clin Pharmacol; 2017 Dec; 25(4):190-195. PubMed ID: 32095474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of a fixed-dose combination of atorvastatin and metformin extended release versus concurrent administration of individual formulations: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study.
    Kandhwal K; Dey S; Nazarudheen S; Arora R; Reyar S; Thudi NR; Monif T; Singh MK; Rao S
    Clin Drug Investig; 2011 Dec; 31(12):853-63. PubMed ID: 21919543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects.
    Chang M; Liu X; Cui D; Liang D; LaCreta F; Griffen SC; Lubin S; Quamina-Edghill D; Boulton DW
    Clin Ther; 2015 Jul; 37(7):1517-28. PubMed ID: 26048185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
    Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS
    Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fed and fasted bioequivalence assessment of two formulations of extended-release fixed-dose combination dapagliflozin/metformin (10/1,000 mg) tablets in healthy subjects.
    Lee HW; Kang WY; Park JS; Lee JH; Gwon MR; Yang DH; Kim EH; Park SJ; Yoon YR; Seong SJ
    Transl Clin Pharmacol; 2023 Jun; 31(2):105-113. PubMed ID: 37440782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
    Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
    J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.
    Boulton DW; Smith CH; Li L; Huang J; Tang A; LaCreta FP
    Clin Drug Investig; 2011; 31(9):619-30. PubMed ID: 21819160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Variables of Dapagliflozin/Metformin Extended-release Fixed-dose Combination in Healthy Chinese Volunteers and Regional Comparison.
    Zhao X; Ning R; Hui A; Boulton DW; Tang W
    Clin Ther; 2023 Aug; 45(8):762-769. PubMed ID: 37442656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects.
    Cho YS; Lee SH; Lim HS; Bae KS
    J Korean Med Sci; 2018 Oct; 33(41):e258. PubMed ID: 30288156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjects.
    Upreti VV; Keung CF; Boulton DW; Chang M; Li L; Tang A; Hsiang BC; Quamina-Edghill D; Frevert EU; Lacreta FP
    Clin Drug Investig; 2013 May; 33(5):365-74. PubMed ID: 23549864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of a Fixed-Dose Combination of Teneligliptin Hydrochloride Hydrate and Modified-Release Metformin Under Fasting and Fed Conditions in Healthy Subjects.
    Goak IS; Lee JA; Jeong MH; Moon SJ; Kim MG
    Drug Des Devel Ther; 2022; 16():4439-4448. PubMed ID: 36597442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of a fixed-dose combination of gemigliptin/metformin sustained release 25/500 mg compared to the loose combination in healthy male subjects.
    Jin X; Kim E; Huh KY; Hwang I; Cho JY; Yu KS; Lee S
    Transl Clin Pharmacol; 2020 Mar; 28(1):43-54. PubMed ID: 32274380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Pharmacokinetics of a Fixed-Dose Combination of Rosuvastatin/Metformin Sustained-Release (10/1000 mg) and Separate Tablets in Healthy Male Subjects.
    Huh KY; Kim E; Lee H; Jeon I; Suh H; Lee J; Lee Y; Yu KS; Lee S
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):207-213. PubMed ID: 32579298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
    Lingvay I; Beetz N; Sennewald R; Schuler-Metz A; Bertulis J; Loley C; Lang B; Lippert C; Lee J; Manning LS; Terada D
    Postgrad Med; 2020 May; 132(4):337-345. PubMed ID: 32366156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tablets.
    Buschke S; Ring A; Friedrich C; Metzmann K; Meinicke T
    Int J Clin Pharmacol Ther; 2014 Jul; 52(7):537-48. PubMed ID: 24755123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets.
    Ghim JL; Phuong NTT; Kim MJ; Kim EJ; Song GS; Ahn S; Shin JG; Kim EY
    Drug Des Devel Ther; 2019; 13():1623-1632. PubMed ID: 31190741
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects.
    Rhee SJ; Lee S; Yoon SH; Cho JY; Jang IJ; Yu KS
    Drug Des Devel Ther; 2016; 10():1411-8. PubMed ID: 27110098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and bioequivalence evaluation of gliclazide/metformin combination tablet and equivalent doses of gliclazide and metformin in healthy Korean subjects.
    Cho HY; Yoon H; Lim YC; Lee YB
    Int J Clin Pharmacol Ther; 2009 Dec; 47(12):770-9. PubMed ID: 19954716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
    Choi HY; Noh YH; Kim YH; Kim MJ; Lee SH; Kim JA; Kim B; Lim HS; Bae KS
    Int J Clin Pharmacol Ther; 2014 May; 52(5):381-91. PubMed ID: 24495314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of a fixed-dose glimepiride/sustained-release metformin combination.
    Kim KP; Lim KS; Kim BH; Shin HS; Cho JY; Shin SG; Jang IJ; Yu KS
    Int J Clin Pharmacol Ther; 2012 Feb; 50(2):142-9. PubMed ID: 22257580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.